Topic
Atrial fibrillation
About: Atrial fibrillation is a research topic. Over the lifetime, 50231 publications have been published within this topic receiving 1357654 citations. The topic is also known as: A-fib & AFib.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: ACCF/AHAIAI: angiotensin-converting enzyme inhibitor as discussed by the authors, angio-catabolizing enzyme inhibitor inhibitor inhibitor (ACS inhibitor) is a drug that is used to prevent atrial fibrillation.
Abstract: ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
7,489 citations
••
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
Abstract: ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
6,757 citations
••
TL;DR: The data suggest that the elderly are particularly vulnerable to stroke when atrial fibrillation is present, and the effects of hypertension, coronary heart disease, and cardiac failure on the risk of stroke became progressively weaker with increasing age.
Abstract: The impact of nonrheumatic atrial fibrillation, hypertension, coronary heart disease, and cardiac failure on stroke incidence was examined in 5,070 participants in the Framingham Study after 34 years of follow-up. Compared with subjects free of these conditions, the age-adjusted incidence of stroke was more than doubled in the presence of coronary heart disease (p less than 0.001) and more than trebled in the presence of hypertension (p less than 0.001). There was a more than fourfold excess of stroke in subjects with cardiac failure (p less than 0.001) and a near fivefold excess when atrial fibrillation was present (p less than 0.001). In persons with coronary heart disease or cardiac failure, atrial fibrillation doubled the stroke risk in men and trebled the risk in women. With increasing age the effects of hypertension, coronary heart disease, and cardiac failure on the risk of stroke became progressively weaker (p less than 0.05). Advancing age, however, did not reduce the significant impact of atrial...
6,692 citations
••
TL;DR: It is confirmed that atrial fibrillation is common among older adults and provides a contemporary basis for estimates of prevalence in the United States.
Abstract: ContextAtrial fibrillation is the most common arrhythmia in elderly persons
and a potent risk factor for stroke. However, recent prevalence and projected
future numbers of persons with atrial fibrillation are not well described.ObjectiveTo estimate prevalence of atrial fibrillation and US national projections
of the numbers of persons with atrial fibrillation through the year 2050.Design, Setting, and PatientsCross-sectional study of adults aged 20 years or older who were enrolled
in a large health maintenance organization in California and who had atrial
fibrillation diagnosed between July 1, 1996, and December 31, 1997.Main Outcome MeasuresPrevalence of atrial fibrillation in the study population of 1.89 million;
projected number of persons in the United States with atrial fibrillation
between 1995-2050.ResultsA total of 17 974 adults with diagnosed atrial fibrillation were
identified during the study period; 45% were aged 75 years or older. The prevalence
of atrial fibrillation was 0.95% (95% confidence interval, 0.94%-0.96%). Atrial
fibrillation was more common in men than in women (1.1% vs 0.8%; P<.001). Prevalence increased from 0.1% among adults younger than
55 years to 9.0% in persons aged 80 years or older. Among persons aged 50
years or older, prevalence of atrial fibrillation was higher in whites than
in blacks (2.2% vs 1.5%; P<.001). We estimate
approximately 2.3 million US adults currently have atrial fibrillation. We
project that this will increase to more than 5.6 million (lower bound, 5.0;
upper bound, 6.3) by the year 2050, with more than 50% of affected individuals
aged 80 years or older.ConclusionsOur study confirms that atrial fibrillation is common among older adults
and provides a contemporary basis for estimates of prevalence in the United
States. The number of patients with atrial fibrillation is likely to increase
2.5-fold during the next 50 years, reflecting the growing proportion of elderly
individuals. Coordinated efforts are needed to face the increasing challenge
of optimal stroke prevention and rhythm management in patients with atrial
fibrillation.
6,054 citations
••
TL;DR: In this paper, the authors provided evidence-based recommendations for the prevention of future stroke among survivors of ischemic stroke or transient ischemi-chemic attack, including the control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke.
Abstract: The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of ischemic stroke or transient ischemic attack. The guideline is addressed to all clinicians who manage secondary prevention for these patients. Evidence-based recommendations are provided for control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke. Recommendations are also provided for the prevention of recurrent stroke in a variety of specific circumstances, including aortic arch atherosclerosis, arterial dissection, patent foramen ovale, hyperhomocysteinemia, hypercoagulable states, antiphospholipid antibody syndrome, sickle cell disease, cerebral venous sinus thrombosis, and pregnancy. Special sections address use of antithrombotic and anticoagulation therapy after an intracranial hemorrhage and implementation of guidelines.
4,545 citations